Discovery of CP-690,550: A potent and selective janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection

Journal of Medicinal Chemistry

Volumn 53, Issue 24, 2010, Pages 8468-8484

  Flanagan, Mark E ^a   Blumenkopf, Todd A ^a   Brissette, William H ^b   Brown, Matthew F ^a   Casavant, Jeffrey M ^a   Shang Poa, Chang ^c   Doty, Jonathan L ^d   Elliott, Eileen A ^a   Fisher, Michael B ^e   Hines, Michael ^a   Kent, Craig ^a   Kudlacz, Elizabeth M ^a   Lillie, Brett M ^a   Magnuson, Kelly S ^a   McCurdy, Sandra P ^a   Munchhof, Michael J ^a   Perry, Bret D ^a   Sawyer, Perry S ^a   Strelevitz, Timothy J ^a   Subramanyam, Chakrapani ^a   Sun, Jianmin ^a   Whipple, David A ^f   Changelian, Paul S ^g   more..

^a PFIZER INC   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d University of Connecticut ^*  (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f UNIVERSITY OF KANSAS   (United States)

^g Lycera Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; CP 352664; INTERLEUKIN 2; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ACTIVE SITE; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RHEUMATOID ARTHRITIS; RODENT; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; BLOOD PROTEINS; CACO-2 CELLS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; DOGS; FEMALE; FIBROBLASTS; GRAFT REJECTION; HUMANS; JANUS KINASES; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS; MALE; MODELS, MOLECULAR; MONOTERPENES; PIPERIDINES; PROTEIN BINDING; PYRIMIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 78650362917     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1004286     Document Type: Article

References (43)

1. Stock, P. G. The year in review - ATC 2002 Am. J. Transplant. 2003, 3, 373-380
2. Hong, J. C.; Kahan, B. D. Immunosuppressive agents in organ transplantation: past, present, and future Semin. Nephrol. 2000, 20, 108-125
3. Darnell, J. E. J.; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 1994, 264, 1415-1421
4. Ghoreschi, K.; Laurence, A.; O'Shea, J. J. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat. Immunol. 2009, 10, 356-360
5. Ghoreschi, K.; Laurence, A.; O'Shea, J. J. Janus kinases in immune cell signaling Immunol. Rev. 2009, 228, 273-287
6. Johnston, J. A.; Bacon, C. M.; Riedy, M. C.; O'Shea, J. J. Signaling by IL-2 and related cytokines: JAKs, STATs and relationship to immunodeficiency J. Leukocyte Biol. 1996, 60, 441-452
7. Oakes, S. A.; Candotti, F.; Johnston, J. A.; Chen, Y. Q.; Ryan, J. J.; Taylor, N.; Liu, X.; Henninghausen, L.; Notarangelo, L. D.; Paul, W. E.; Blaese, R. M.; O'Shea, J. J. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways Immunity 1996, 5, 605-615
8. Chen, M.; Cheng, A.; Chen, Y. Q.; Hymel, A.; Hanson, E. P.; Kimmel, L.; Minami, Y.; Taniguchi, T.; Changelian, P. S.; O'Shea, J. J. The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 6910-6915
9. Hofmann, S. R.; Ettinger, R.; Zhou, Y. J.; Gadina, M.; Lipsky, P.; Siegel, R.; Candotti, F.; O'Shea, J. J. Cytokines and their role in lymphoid development, differentiation and homeostasis Curr. Opin. Allergy Clin. Immunol. 2002, 2, 495-506
10. Macchi, P.; Villa, A.; Giliani, S.; Sacco, M. G.; Frattini, A.; Porta, F.; Ugazio, A. G.; Johnston, J. A.; Candotti, F.; O'Shea, J. J. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) Nature 1995, 377, 65-68
11. Noguchi, M.; Rosenblatt, H. M.; Filipovich, A. H.; Adelstein, S.; Modi, W. S.; McBride, O. W.; Leonard, W. J. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans Cell 1993, 73, 147-157
12. Russell, S. M.; Tayebi, N.; Nakajima, H.; Riedy, M. C.; Roberts, J. L.; Aman, M. J.; Migone, T. S.; Noguchi, M.; Markert, M. L.; Buckley, R. H.; O'Shea, J. J.; Leonard, W. J. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development Science 1995, 270, 797-800
13. Pesu, M.; Candotti, F.; Husa, M.; Hofmann, S. R.; Notarangelo, L. D.; O'Shea, J. J. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs Immunol. Rev. 2005, 203, 127-142
14. Changelian, P. S.; Flanagan, M. E.; Ball, D. J.; Kent, C. R.; Magnuson, K. S.; Martin, W. H.; Rizzuti, B. J.; Sawyer, P. S.; Perry, B. D.; Brissette, W. H.; McCurdy, S. P.; Kudlacz, E. M.; Conklyn, M. J.; Elliott, E. A.; Koslov, E. R.; Fisher, M. B.; Strelevitz, T. J.; Yoon, K.; Whipple, D. A.; Sun, J.; Munchhof, M. J.; Doty, J. L.; Casavant, J. M.; Blumenkopf, T. A.; Hines, M.; Brown, M. F.; Lillie, B. M.; Subramanyam, C.; Shang-Poa, C.; Milici, A. J.; Beckius, G. E.; Moyer, J. D.; Su, C.; Woodworth, T. G.; Gaweco, A. S.; Beals, C. R.; Littman, B. H.; Fisher, D. A.; Smith, J. F.; Zagouras, P.; Magna, H. A.; Saltarelli, M. J.; Johnson, K. S.; Nelms, L. F.; Des Etages, S. G.; Hayes, L. S.; Kawabata, T. T.; Finco-Kent, D.; Baker, D. L.; Larson, M.; Si, M. S.; Paniagua, R.; Higgins, J.; Holm, B.; Reitz, B.; Zhou, Y. J.; Morris, R. E.; O'Shea, J. J.; Borie, D. C. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Science 2003, 302, 875-878
15. West, K. CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders Curr. Opin. Invest. Drugs 2009, 10, 491-504
16. Sorbera, L. A.; Serradell, N.; Bolos, J.; Rosa, E.; Bozzo, J. CP-690,550 Drugs Future 2007, 32, 674-680
17. Wrobleski, S. T.; Pitts, W. J. Chapter 12 Advances in the discovery of small molecule JAK3 inhibitors Annu. Rep. Med. Chem. 2009, 44, 247-264
18. Kudlacz, E.; Perry, B.; Sawyer, P.; Conklyn, M.; McCurdy, S.; Brissette, W.; Flanagan, A.; Changelian, P. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models Am. J. Transplant. 2004, 4, 51-57
19. Meyer, D. M.; Jesson, M. I.; Li, W.; Elrick, M. M.; Funckes-Shippy, C. L.; Warner, J. D.; Gross, C. J.; Dowty, M. E.; Ramaiah, S. K.; Hirsch, J. L.; Saabye, M. J.; Barks, J. L.; Kishore, N.; Morris, D. L. Anti-inflammatory activity and neutrophil reductions mediated by JAK1 and JAK3 inhibition in the rat AIA model. J. Inflammation (London) 2010, 7, 41.
20. Simonsen, J. The Terpenes; Cambridge University Press: Cambridge, 1953; pp 394-408.
21. Brown Ripin, D. H.; Abele, S.; Cai, W.; Blumenkopf, T.; Casavant, J. M.; Doty, J. L.; Flanagan, M.; Koecher, C.; Laue, K. W.; McCarthy, K.; Meltz, C.; Munchhof, M. J.; Pouwer, K.; Sha, B.; Sun, J.; Teixeira, J.; Vries, T.; Whipple, D. A.; Wilcox, G. Development of a scaleable route for the production of cis-N -benzyl-3-methylamino-4-methylpiperidine Org. Process Res. Dev. 2003, 7, 115-120
22. Jiang, J. K.; Ghoreschi, K.; Deflorian, F.; Chen, Z.; Perreira, M.; Pesu, M.; Smith, J.; Nguyen, D. T.; Liu, E. H.; Leister, W.; Costanzi, S.; O'Shea, J. J.; Thomas, C. J. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl) amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550) J. Med. Chem. 2008, 51, 8012-8018
23. Williams, N. K.; Bamert, R. S.; Patel, O.; Wang, C.; Walden, P. M.; Wilks, A. F.; Fantino, E.; Rossjohn, J.; Lucet, I. S. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains J. Mol. Biol. 2009, 387, 219-232
24. Chrencik, J. E.; Patny, A.; Leung, I. K.; Korniski, B.; Emmons, T. L.; Hall, T.; Weinberg, R. A.; Gormley, J. A.; Williams, J. M.; Day, J. E.; Hirsch, J. L.; Kiefer, J. R.; Leone, J. W.; Fischer, H. D.; Sommers, C. D.; Huang, H. C.; Jacobsen, E. J.; Tenbrink, R. E.; Tomasselli, A. G.; Benson, T. E. Structural and thermodynamic characterization of the TYK2 and JAK3 kinase domains in complex with CP-690550 and CMP-6 J. Mol. Biol. 2010, 400, 413-433
25. World Intellectual Property Organization. (WO/2003/048162) Novel Crystalline Compound. http://www.wipo.int/pctdb/en/wo.jsp?wo=2003048162&IA= IB2002004948&DISPLAY=DOCS. Accessed 3 August 2010.
26. van Gurp, E.; Weimar, W.; Gaston, R.; Brennan, D.; Mendez, R.; Prusch, J.; Swan, S.; Pescovitz, M. D.; Ni, G.; Wang, C.; Krishnaswami, S.; Chow, V.; Chan, G. Phase 1 dose-escalation study of CP-690-550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics Am. J. Transplant. 2008, 8, 1711-1718
27. Lawendy, N.; Krishnaswami, S.; Wang, R.; Gruben, D.; Cannon, C.; Swan, S.; Chan, G. Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers J. Clin. Pharmacol. 2009, 49, 423-429
28. Dalvie, D.; Obach, R. S.; Kang, P.; Prakash, C.; Loi, C. M.; Hurst, S.; Nedderman, A.; Goulet, L.; Smith, E.; Bu, H. Z.; Smith, D. A. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites Chem. Res. Toxicol. 2009, 22, 357-368
29. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Flloyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A qualitive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
30. Pfizer Inc. Data on file. 2009.
31. Borie, D. C.; Larson, M. J.; Flores, M. G.; Campbell, A.; Rousvoal, G.; Zhang, S.; Higgins, J. P.; Ball, D. J.; Kudlacz, E. M.; Brissette, W. H.; Elliott, E. A.; Reitz, B. A.; Changelian, P. S. Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates Transplantation 2005, 80, 1756-1764 (Pubitemid 43054002)
32. Rousvoal, G.; Si, M. S.; Lau, M.; Zhang, S.; Berry, G. J.; Flores, M. G.; Changelian, P. S.; Reitz, B. A.; Borie, D. C. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy Transplant Int. 2006, 19, 1014-1021
33. Busque, S.; Leventhal, J.; Brennan, D.; Steinberg, S.; Klintmalm, G.; Shah, T.; Mulgaonkar, S.; Bromberg, J.; Vincenti, F.; Hariharan, S.; Slakey, D.; Peddi, V. R.; Fisher, R. A.; Lawendy, N.; Wang, C.; Chan, G. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP690,550: a pilot study in de novo kidney allograft recipients Am. J. Transplant. 2009, 9, 1936-1945
34. Milici, A. J.; Kudlacz, E. M.; Audoly, L.; Zwillich, S.; Changelian, P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis Arthritis Res. Ther. 2008, 10, R14
35. Kremer, J. M.; Bloom, B. J.; Breedveld, F. C.; Coombs, J. H.; Fletcher, M. P.; Gruben, D.; Krishnaswami, S.; Burgos-Vargas, R.; Wilkinson, B.; Zerbini, C. A. F.; Zwillich, S. H. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dose levels of CP-690,550 versus placebo Arthritis Rheum. 2009, 60, 1895-1905
36. Kremer, J. M.; Cohen, S.; Wilkinson, B.; Connell, C; French, J; Gomez Reino, J; Gruben, D.; Kanik, K; Krishnaswami, S.; Pascual-Ramos, V; Wallenstein, G; Zwillich, S. The oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) is efficacious, safe and well tolerated in patients with active rheumatoid arthritis (RA) with an inadequate response to methotrexate alone Arthritis Rheum. 2008, 58, 4030
37. Kremer, J. M.; Cohen, S.; Wilkinson, B.; Gruben, D.; Wallenstein, G; Kanik, K; Zwillich, S. H. Safety and efficacy after 24 week (WK) dosing of the oral JAK inhibitor CP-690,550 (CP) in combination with methotrexate (MTX) in patients (PTS) with active rheumatoid arthritis (RA) Arthritis Rheum. 2009, 60 (Suppl. 10) S719, 1925 (abstract)
38. Kanik, K.; Fleischmann, R.; Cutolo, M.; Genovese, M.; Lee, E.; Sadis, S.; Connell, C.; Gruben, D.; Krishnaswami, S.; Wallenstein, G.; Wilkinson, B.; Zwillich, S. Phase 2b dose ranging monotherapy study of the oral JAK inhibitor CP-690,550 (CP) or adalimumab (ADA) vs placebo (PBO) in patients (pts) with active rheumatoid arthritis (RA) with an inadequate response to DMARDs Ann. Rheum. Dis. 2009, 68 (Suppl. 3) 123, OP-0159 (abstract)
39. Fleischmann, R. M.; Genovese, M. C.; Gruben, D.; Kanik, K; Wallenstein, G; Wilkinson, B.; Zwillich, S. H. Safety and efficacy after 24 week (wk) dosing of the oral JAK inhibitor CP-690,550 (CP) as monotherapy in patients (pts) with active rheumatoid arthritis (RA) Arthritis Rheum. 2009, 60 (Suppl. 10) S718, 1924 (abstract)
40. Kalgutkar, A. S.; Choo, E.; Taylor, T. J.; Marfat, A. Disposition of CP-671,305, a selective phosphodiesterase 4 inhibitor in preclinical species Xenobiotica 2004, 34, 755-770
41. Obach, R. S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression J. Pharmacol. Exp. Ther. 2000, 294, 88-95
42. Kalgutkar, A. S.; Hatch, H. L.; Kosea, F.; Nguyen, H. T.; Choo, E. F.; McClure, K. F.; Taylor, T. J.; Henne, K. R.; Kuperman, A. V.; Dombroski, M. A.; Letavic, M. A. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a] pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes Biopharm. Drug Dispos. 2006, 27, 371-386
43. Davoll, J. Pyrrolo[2,3-d]pyrimidines J. Chem. Soc. 1960, 82, 131-138